- Details
- Description
-
Packaging Size1bottle/Box
-
Strength100mg(4mL)
-
CompositonSocazolimab
-
TreatmentRecurrent or metastatic cervical cancer
-
FormInjection
-
Brand善克钰
-
Quantity Unit100mg(4mL)/1/Box
-
ManufacturerLee's Pharmaceutical.,China
Socazolimab is a fully human anti-PD-L1 (programmed cell death 1 ligand 1) monoclonal antibody, an immune checkpoint inhibitor, developed by Sorrento.
- Socazolimab sold under the brand name 善克钰® in china.
On December 21, 2023, the official website of the China National Medical Products Administration (NMPA) announced that the anti-PD-L1 monoclonal antibody socazolimab, applied for by Zhaoke Oncology, a subsidiary of Lee's Pharmaceutical, has been officially approved for the treatment of recurrent or metastatic cervical cancer.